Redhill Biopharma - ADR Share Price Today

RedHill partner OU secures $2.9M NCI grant for opaganib trials

University of Oklahoma received $2.9 million from NCI for clinical trials. Trials evaluate RedHill's opaganib combined with CAR T-cell therapy. Phase 1b enrolls up to 18 patients for safety and dosage assessment. Phase 2 enrolls up to 21 patients for preliminary effectiveness data. CAR T cells manufactured on-site at OU campus to save time and money.

RedHill Biopharma H1FY27 Results: Net loss widens 48% YoY to $6.1M

Net loss widened 48% YoY to $6.1 million in H1FY27. Revenue dropped to $0.00 from $0.3 million in prior year. EPS reported at $0.00 with no dividend declared. Total liabilities rose to $27.4 million due to derivative instruments.

RedHill Biopharma acquires Rebyota, Clenpiq rights from Ferring for $12 million

RedHill Biopharma acquired global rights to Rebyota and U.S. rights to Clenpiq from Ferring for $12 million upfront. The deal was fully funded by $18 million in proceeds from the Talicia divestiture, leaving RedHill with $6 million in additional cash. The acquired assets generated combined U.S. net sales of $37.5 million in 2025, comprising $16.9 million for Rebyota and $20.6 million for Clenpiq. Rebyota holds Orphan Drug designation with patent protections potentially lasting until 2036, while Clenpiq has broad payer coverage for over 108 million lives. The transaction completes a strategic repositioning of RedHill’s GI business into a larger, fully controlled commercial portfolio.

RedHill Biopharma stock jumps 95% after $18M Talicia divestment

RedHill Biopharma stock surged 95.17% to $1.29 on Monday following the Talicia divestment announcement. The company sold its 70% stake in Talicia to Apotex for $18 million upfront plus up to $35 million in milestones. Trading volume hit 68.7 million shares, reflecting strong investor interest in the liquidity boost. Proceeds will fund commercial expansion and new FDA-approved product opportunities. The stock remains 53.8% below its 52-week high despite the sharp single-day gain.

RedHill Biopharma closes $19.4M private placement

RedHill Biopharma Ltd. closed a private placement on June 22, 2026, raising $6 million upfront through the sale of ADSs and warrants. The offering includes potential additional proceeds of $13.4 million if warrants are exercised, aimed at supporting strategic acquisitions and corporate purposes.

RedHill Biopharma secures FDA Rare Pediatric Disease Designation for opaganib

RedHill Biopharma Ltd. announced that the U.S. FDA granted Rare Pediatric Disease designation to opaganib for neuroblastoma, complementing its existing Orphan Drug status. This designation offers potential benefits such as a Priority Review Voucher, fee waivers, and seven years of marketing exclusivity. New preclinical data presented at the 2026 AACR Annual Meeting showed positive effects of opaganib in neuroblastoma and triple-negative breast cancer models, with the neuroblastoma market projected to reach $3.5 billion by 2032.